IMAC Regeneration Centers
IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC owns or manages 15 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies, focusing on treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. The company emphasizes its commitment to innovative healthcare solutions and personalized medicine, with a focus on advancing regenerative and proteomic technologies.
Industries
Nr. of Employees
medium (51-250)
IMAC Regeneration Centers
Paducah, Kentucky, United States, North America
Products
Advanced proteomic breast cancer assay (PLA code 0249U)
A clinically validated, multi-marker proteomic assay that quantifies protein expression and activation (phosphorylation) in breast tumor samples to predict response to targeted therapies.
Mesenchymal stem cell therapy candidate (Phase I)
An early‑stage regenerative medicine therapeutic candidate evaluated in a Phase I clinical trial for treatment of bradykinesia associated with Parkinsonian symptoms.
Advanced proteomic breast cancer assay (PLA code 0249U)
A clinically validated, multi-marker proteomic assay that quantifies protein expression and activation (phosphorylation) in breast tumor samples to predict response to targeted therapies.
Mesenchymal stem cell therapy candidate (Phase I)
An early‑stage regenerative medicine therapeutic candidate evaluated in a Phase I clinical trial for treatment of bradykinesia associated with Parkinsonian symptoms.
Services
Outpatient regenerative and orthopedic clinical services
Operation and management of outpatient clinics delivering regenerative rehabilitation, minimally invasive orthopedic procedures, and therapies for movement‑restricting conditions.
Proteomic laboratory testing services (clinical diagnostic assays)
Provision of CLIA/CAP/State-approved laboratory-developed proteomic assays that measure protein expression and activation in tumor samples to inform therapy selection.
Clinical research services and trial collaborations
Analytical support for clinical trials and collaborative biomarker studies, including analysis of trial datasets and publication/presentation of findings.
Outpatient regenerative and orthopedic clinical services
Operation and management of outpatient clinics delivering regenerative rehabilitation, minimally invasive orthopedic procedures, and therapies for movement‑restricting conditions.
Proteomic laboratory testing services (clinical diagnostic assays)
Provision of CLIA/CAP/State-approved laboratory-developed proteomic assays that measure protein expression and activation in tumor samples to inform therapy selection.
Clinical research services and trial collaborations
Analytical support for clinical trials and collaborative biomarker studies, including analysis of trial datasets and publication/presentation of findings.
Expertise Areas
- Proteomic diagnostics
- Biomarker validation and clinical utility studies
- Clinical trial support and translational analytics
- Clinical laboratory operations and regulatory compliance (CLIA/CAP/state)
Key Technologies
- Reverse-phase protein array (RPPA)
- Phosphoprotein / phosphoproteomics
- Multi-analyte proteomic assays
- Rules-based artificial intelligence for assay interpretation